CagriSema (Cagrilintide B + semaglutide I) for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Sep 2025: Trial registered, NCT07184086
  2. 26 Sep 2025: Trial started, NCT07184086

The trials

NCT07184086: A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

State
Under way
Phase
Phase 1
People
80 planned
Started
26 Sep 2025
Primary completion
12 Oct 2027
Arms
CagriSema (Cagrilintide + Semaglutide) / CagriSema
Results
None posted
  1. 19 Sep 2025: Trial registered
  2. 26 Sep 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.